All In Biotech

Drug Trial Radar · NCT00536484

Fesoterodine Flexible Dose Study

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Overactive Bladder.

Last checked: Nov 20, 2026Latest source record: Sep 15, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 896 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

896

Actual

Start

Aug 2007

Primary completion

Mar 2008

Study completion Mar 2008

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 27, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3B study is designed to test if a fesoterodine flexible dose regimen is more effective than placebo in reducing micturition frequency and other overactive bladder (OAB) symptoms, e.g., urgency, urgency incontinence episodes in patients with overactive bladder and if the fesoterodine regimen is safe and well tolerated.

Conditions

  • Overactive Bladder

Interventions

  • FesoterodineDrug

    4mg tablets once daily for 2 weeks, then either 4mg or 8mg tablets once daily for 10 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.

  • PlaceboDrug

    Matched placebo tablets once daily for 12 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Mean Number of Micturition Episodes Per 24 Hours at Week 12 Relative to Baseline.Time frame: Baseline and Week 12

Locations

95 sites in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Mobile, Alabama

  • Pfizer Investigational Site

    Chandler, Arizona

  • Pfizer Investigational Site

    Peoria, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Rancho Cordova, California

  • Pfizer Investigational Site

    Sacramento, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    Englewood, Colorado

  • Pfizer Investigational Site

    New Britain, Connecticut

  • Pfizer Investigational Site

    Aventura, Florida

  • Pfizer Investigational Site

    Bonita Springs, Florida

  • Pfizer Investigational Site

    Hollywood, Florida

  • Pfizer Investigational Site

    Lake Worth, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Naples, Florida

  • Pfizer Investigational Site

    Pembroke Pines, Florida

  • Pfizer Investigational Site

    St. Petersburg, Florida

  • Pfizer Investigational Site

    Stuart, Florida

  • Pfizer Investigational Site

    Tallahassee, Florida

  • Pfizer Investigational Site

    Chicago, Illinois

  • Pfizer Investigational Site

    Evansville, Indiana

  • Pfizer Investigational Site

    Jeffersonville, Indiana

  • Pfizer Investigational Site

    Newburgh, Indiana

  • Pfizer Investigational Site

    Iowa City, Iowa

  • Pfizer Investigational Site

    Overland Park, Kansas

  • Pfizer Investigational Site

    Overland Park, Kansas

  • Pfizer Investigational Site

    Pratt, Kansas

  • Pfizer Investigational Site

    Lexington, Kentucky

  • Pfizer Investigational Site

    Louisville, Kentucky

  • Pfizer Investigational Site

    Louisville, Kentucky

  • Pfizer Investigational Site

    Madisonville, Kentucky

  • Pfizer Investigational Site

    Baltimore, Maryland

  • Pfizer Investigational Site

    Bel Air, Maryland

  • Pfizer Investigational Site

    Milford, Massachusetts

  • Pfizer Investigational Site

    Springfield, Massachusetts

  • Pfizer Investigational Site

    West Yarmouth, Massachusetts

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.